Biotech News

Rapid Micro Biosystems Reports Third Quarter 2026 Financial Results

Rapid Micro Biosystems (RPID)Rapid Micro BiosystemsEarnings

Reports third quarter 2026 total revenue of $9.5 million, representing 22% growth compared to the third quarter of 2025 Placed 7 Growth Direct systems and completed 12 validations in the third quarter of 2026 Reports record third quarter 2026 total gross margin of 25%, an increase of 16 percentage

Related news

Rapid Micro Biosystems

Automated Microbial Quality Control Rapid Micro Biosystems provides automation systems used to test biologics, vaccines, cell and gene therapies, sterile injectables, and other healthcare products for microbial contamination. Growth Direct Platform The Growth Direct system replaces manual microbial quality-control workflows with...

Recent company news

Stock data

Close
0.74 USD
Market cap
97.65M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States